NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.373) was uploaded to the NHS England Website on Thursday 4, September 2025.
The following changes have been introduced:
Isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (ISA2)
in combination (with bortezomib, lenalidomide, and dexamethasone) for the treatment of UNTREATED multiple myeloma when a stem cell transplant is UNSUITABLE where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Capivasertib in combination with fulvestrant (CAP1)
Capivasertib in combination with fulvestrant for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in patients previously treated with a CDK4/6 inhibitor and an aromatase inhibitor where the following criteria have been met
Moved into routine commissioning - section B of list
NA (DOS2)
NA
Moved into routine commissioning - section B of list
Nivolumab with ipilimumab (NIV24)
Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Moved into routine commissioning - section B of list
Pembrolizumab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) (PEMB32)
Pembrolizumab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) for the 1st line treatment of mismatch repair deficient (dMMR) or microsatellite instability-high endometrial carcinoma in adult patients who have recurrent or primary advanced disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy but are eligible for systemic therapy where the following criteria have been met
Date moving into routine commissioning updated